[Antacids for postoperative prevention of stress ulcer in infants: a dose finding study]

H Kentrup1, H Skopnik, L Wolter

  • 1Kinderklinik, Med. Einrichtungen der RWTH Aachen.

Klinische Padiatrie
|January 1, 1996
PubMed

Insights

Standard antacid dosages are too high for infants. A reduced dose of 0.25 ml/kg, given six times daily, effectively maintains gastric pH in infants undergoing cardiosurgery.

Area of Science:

  • Pediatric Gastroenterology
  • Neonatal Critical Care
  • Pharmacology

Background:

  • Infant gastric acid secretion increases exponentially in the first six months of life.
  • Current antacid prophylaxis for stress ulcers in infants lacks age-specific dosage recommendations.
  • Adult antacid dosages are inappropriate for pediatric use due to physiological differences.

Purpose of the Study:

  • To evaluate optimal antacid dosing strategies for stress ulcer prophylaxis in infants.
  • To compare the efficacy of two different antacid regimens in maintaining gastric pH.
  • To inform evidence-based antacid dosage recommendations for neonates.

Main Methods:

  • A crossover study involving 12 infants (4-174 days old) post-cardiosurgery.
  • Continuous gastric pH monitoring over 48 hours with two 24-hour antacid regimens (A and B).
  • Regimen A: 0.5 ml/kg every 4 hours; Regimen B: 0.25 ml/kg when pH < 3, checked every 30 minutes.

Main Results:

  • Regimen B resulted in significantly lower mean administered antacid dose (2.2 ml) compared to Regimen A (12.0 ml).
  • Regimen A achieved a higher mean gastric pH (median 5.96) than Regimen B (median 4.94).
  • Lower pH (<3) was more frequent with Regimen B, but longer durations at this pH occurred with Regimen A.

Conclusions:

  • Standard body weight-based antacid dosages appear excessive for infants.
  • Reducing the single antacid dose to 0.25 ml/kg with frequent administration (6 times/day) is a reasonable approach for this age group.
  • Further research into age-specific antacid dosing is warranted for effective stress ulcer prophylaxis in neonates.
Abstract

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease